Showing posts with label Miscarriage. Show all posts
Showing posts with label Miscarriage. Show all posts

Miscarriages and Immunotherapy: Overview by Dr. William L. Matzner

Dr. William Matzner, Simi Valley, California
Dr. William L. Matzner of Simi Valley, California

Miscarriages and Immunotherapy

Some patients are uncomfortable about taking any medication during pregnancy. Rest assured that a competent medical professional will decide all medication and doses after giving it thorough consideration to minimize any drug related side effects.

As your pregnancy progresses your blood test results may change, justifying a modification in your medication regime. If changes are indicated, your medical provider should communicate the changes to you immediately.

If at any time you have questions regarding medications or suspect that you are having an allergic reaction or side effect, please discuss them with your caregiver right away. 

Aspirin 

Aspirin is an antiinflammatory and antiplatelet agent. Should you require low dose aspirin, the recommendation is 80 mg per day, which is equivalent to a baby aspirin.

Aspirin, like all medication, can cause allergic reactions. Manifestations of aspirin allergy may include dermatitis, rhinitis, bronchospasm and even anaphylaxis. People who have a history of asthma and nasal polyps are at increased risk for allergic reactions.

Side effects of low dose aspirin are infrequent but can include nausea, reflux esophagitis, abdominal discomfort, anorexia and gastrointestinal and urinary tract bleeding. Use of high dose aspirin during pregnancy may affect maternal and neonatal blood clotting mechanisms, leading to an increased risk of bleed. High dose aspirin may also impair maternal kidney function and has been causally related to increased perinatal mortality, intrauterine growth retardation and congenital defects. Aspirin at low doses has not been associated with these risks.

Aspirin is excreted into breast milk in low concentration ranging from 1.1 to 10 mcg/ml. Adverse effects of platelet function in the nursing infants have not been reported, but are a potential risk. If you choose to breast feed your baby you should not take aspirin at that time. 

Routine laboratory testing while on aspirin should include complete blood count, chemistries, APTT and antiphospholipid antibody panel. 

Heparin 

Heparin, an anticoagulant, is a purifies preparation derived from animal tissue. It is delivered as a subcutaneous injection and a typical dose would be 5000 IU twice a day.  

Allergic reactions may include chills, fever, dermatitis, asthma and anaphylactic shock. Before a therapeutic dose is administered, a trial of 1000 IU would be prudent. Fortunately, allergy to heparin is rare.

Because of heparin's blood "thinning" property the user is more susceptible to bleeding (skin, nose, gastrointestinal tract, bladder, etc.). Almost all patients experience some bruising at the site where heparin is injected.

Long term heparin therapy has been associated with osteoporosis and spontaneous fractures in patients who have received in excess of 15,000 units per day for more than six months. One study of 117 patients on long term heparin (up to 15 years) report no spontaneous fracture when subjects received less that 10,000 units per day. Although our protocol utilizes low dose heparinization, supplementation (dietary) with calcium is recommended. Exercise and sun tanning may also prevent osteoporosis.

Heparin has not been related to congenital defects, nor does it cross the placenta. Heparin use during pregnancy has been associated with a 13 to 22% unfavorable pregnancy outcome including premature and still birth. Please note that the study group consisted of women who had severe maternal disease necessitating high dose anticoagulant therapy. Although heparin is the preferred anticoagulant during pregnancy it is not risk free. 

Heparin is not excreted in breast milk.

Relative contraindications to the use of heparin are active bleeding, hemophilia, thrombocytopenia or other blood dyscrasia, endocarditis or tuberculosis. Caution should be exercised when there is underlying hypertension and liver kidney disease. 

Routine platelet, hematocrit, APTT and antiphospholipid antibody panel monitoring during heparinization is recommended. 

Administration of Heparin Subcutaneously 

1.                   Wipe the area with alcohol. Do not rub! 

2.                   Remove cap from needle and gently pick up a well defined fold of skin.

3.                   Hold the syringe in a dart fashion and insert the needle directly into the skin at a 45-90 degree angle just into the subcutaneous “fatty layer” of the skin.
4.                   Push down on plunger slowly as far as it will go.
5.                   When all the heparin has been injected, slowly withdraw the needle at the same angle at which it entered, and also releasing the skin roll as you withdraw.
6.                   Apply band aid only if necessary. The site may be irritated by the removal of the band aid, thus causing increased bruising. 

Important Points to Remember 
1.                   Preferred site of injection is the abdominal area. Injections must be given 2 inches away from the umbilicus. If you need another area to give your heparin, you may use your thighs or buttocks.
2.                   Rotate your sites of injections. Avoid injecting a bruised area.
3.                   Some bruising at the sight of injection is normal (less than quarter size). If increased bruising occurs, you may use ice before you clean the area for injection and/or after you have given yourself the injection.
4.                   Notify your doctors before any medication or surgical procedure that you are taking heparin.
5.                   Carry an identification card in your wallet stating that you are on heparin.
6.                   Contact your doctor if any of the following symptoms occur: nose bleeds, blood in the urine of stool, excessive bleeding lasting greater than 15 minutes and not controlled by direct pressure, unusual knot at the site of injection. 

Prednisone 

Prednisone is a corticosteroid. If indicated, you will be asked to take 5 or 10 mg orally twice a day upon confirmation of pregnancy (patients with immune mediated infertility may be on a different schedule). Drug dosage may be adjusted depending upon follow-up blood tests.

Allergy to prednisone is rare, as the human body manufactures a similar compound. In fact prednisone is used to treat moderate to life threatening allergies. 

Possible adverse reaction to moderate and high doses of prednisone include fluid and electrolyte imbalance; metabolic disturbances e.g. hyperglycemia or gestational diabetes and osteoporosis; susceptibility to infection; peptic ulcer; behavioral changes e.g. nervousness, insomnia, irritability and mood swings; myopathy; and cataracts. 

Prednisone should be used with caution in people with hypertension, congestive heart failure, diabetes mellitus, osteoporosis, ulcerative colitis, ocular herpes and others (please consult with doctor if you have any chronic illness). Osteoporosis can be retarded with calcium supplementation and exercise.

Rapid withdrawal of prednisone may cause fatigue, myalgias, arthralgias, dizziness, hypotension, hypoglycemia and dyspnea. If you experience these symptoms, please contact your doctor.

There are a number of studies that review the use of prednisone during pregnancy and effects on the fetus. The fetus appears to be protected by at least three mechanisms: 1) enzymes in the placenta degrade the drug to an inactive form, 2) prednisone in maternal circulation is bound to a large protein making it harder to cross the placenta and 3) fetal liver is not able to activate prednisone until the end of the second trimester.

Trace amounts of prednisone have been measured in breast milk. Although these quantities are of doubtful clinical significance, your baby's pediatrician should be notified.

Laboratory studies to monitor while on prednisone include complete blood count, chemistries, electrolytes and antinuclear antibody panel. 

Immunoglobulin G Infusion 

Immunoglobulin G is a preparation of human derived antibodies. In some patients, conventional immunotherapy with aspirin, heparin and paternal white cell immunization may have to be supplemented with this medication. Patients at risk for developing intrauterine growth retardation, oligohydramnios, toxemia, or severe side effects of steroids, or have preexisting maternal disease are prime candidates. If you require this treatment, it is given intravenously three consecutive days monthly during pregnancy.

Immunoglobulin G is contraindicated in patients who are known to have had anaphylactic or severe systemic reaction to human immune globulin. Patients with IgA deficiency should not receive this product.

Side effects to immunoglobulin G include fever, chills, headache, nausea, malaise and back pain. Mild erythema following infiltration at the sire of infusion has been reported.

Laboratory tests that need to be followed while on this treatment are quantitative immunoglobulins and immunophenotype. 

Paternal Leukocyte Immunization 

Paternal leukocyte immunization (PLI), a purified preparation of husband's white blood cell, is administered intradermally. Because this is a blood product, the recipient (wife) risks acquiring infectious diseases that donor (husband) may harbor. Rh sensitization is also possible; however, extensive steps are taken to prevent this.

Most women will experience redness and itching at the site of immunization. Please notify your doctor if you have any unexpected or serious reaction.

Maternal antipaternal leukocyte antibodies (blocking antibodies), by flow cytometry, should be followed to monitor efficacy of treatment.

***About William L. Matzner, M.D., PhD, FACP 

Dr. William Matzner works in the area of healthcare economics consulting at Healthcare Analytics, LLC, in California. He graduated Phi Beta Kappa from Stanford University. He received his M.D. with Honors from Baylor College of Medicine. In 1988, he was the Solomon Scholar for Resident Research at Cedar Sinai Medical Center. Dr. Matzner subsequently was awarded a PhD in Neuro Economics from Claremont Graduate University. He is board certified in Internal Medicine and Palliative Medicine. He has researched and published extensively on the issue of reproduction and immunology in medical literature. He has been in private practice since 1989, specializing in Reproductive Immunology and Internal medicine. 

Website: https://drwilliammatzner.com 
Consulting Website: https://healthcareanalytics.biz 
LinkedIn: https://www.linkedin.com/in/william-matzner-md-phd-mba-60219730 
Blog: https://drwilliammatzner.blogspot.com 
News: https://hype.news/dr-william-matzner/ 
News: https://hippocratesguild.com/dr-william-matzner 
News: https://medicogazette.com/dr-william-matzner
William Matzner, MD (Simi Valley, California), has been practicing medicine since 1989, Internal Medicine and Reproductive Immunology. M.D. with Honors from Baylor College of Medicine.

Miscarriages can be prevented: Overview by Dr. William Matzner

WIlliam Matzner, MD, Simi Valley, CA
William Matzner, MD., Simi Valley, CA

Miscarriages can be prevented: Overview by Dr. William Matzner


Dr. William Matzner provides an overview on preventing miscarriage. 

An unexpected miscarriage can shatter dreams. Two more can be devastating. But now there is hope, and a solution. One in every 200 couples are too genetically similar to achieve successful pregnancy. And usually, they don't know it. That's why early detection is vital. Without intervention, the painful pattern of miscarriage occurs again and again. 


Introduction 

One in two hundred couples will experience two or more consecutive miscarriages. There are five reasons for miscarriage which have been identified: (1) Infection; (2) Anatomy abnormal; (3) Progesterone level low; (4) Chromosome abnormal; (5) Immune mechanisms.  There may also be unknown or undiagnosed reasons and some women have multiple reasons for miscarriages.  Your obstetrician will test for most other causes of pregnancy loss. 

Immune Systems 

Advances in immunology, the study of the body's defense systems, enable us to understand how during pregnancy, the mother's immune system is altered so that the fetus is not rejected by her body and allows the fetus to grow. 

The immune system is comprised of white blood cells, also known as leukocytes, which make a variety of antibodies . Some of the antibodies protect us and others are harmful to our bodies. Some of the antibodies that are important to the reproductive system are: Blocking (protective) antibodies, Antiphospholipid antibodies, and Antinuclear antibodies.  

When the immune system is the cause of miscarriage, the chances of mother having a successful pregnancy without treatment after 3 miscarriages is 30%, after 4 miscarriages 25%, and after 5 miscarriages 5%. With proper treatment, overall success is 80%!

Blocking Antibodies 

Early in pregnancy, the mother's immune system receives signals from the tiny fetus. Many of the signals are hormonal, but others come directly from genetic messages that the father has contributed. Some of the messages involve the tissue type, also known as the human leukocyte antigens (HLA) are the white blood cell (leukocyte) type. HLA are expressed on white blood cells. They are unique to each individual and allow the body to identify anything foreign to it such as infections, cancers, transplanted organs and fetuses. One half of the fetus's HLA type is contributed by mother and the other half by father. When a woman becomes pregnant, her body's immune system usually recognizes the father's HLA as different from her own, and the white blood cells in her uterus produce protective, blocking antibodies. These antibodies coat the baby's cells and protect the fetus from mother's killer cells (figure 1). 


If father's HLA is too similar to mother's, her cells may not recognize differences that are vital to the production of blocking antibodies. 


Women who have successful pregnancies and have no history of miscarriages normally, have high levels of blocking antibodies even in the non pregnant state vs women who miscarry and whose levels tend to be low even when pregnant.

Through HLA tissue typing we can identify couples who look too much "alike" In addition we can measure the ability of a couple's cells to respond to each other i.e. level of blocking antibodies, using sophisticated equipment which combine computers and laser (cell flow cytometry).

Treatment involves immunizing mother with concentrates of father's white blood cells so that the HLA signal is amplified. When blocking levels are elevated, prior to conception, the rate of successful term pregnancy is approximately 80%.  


The risk associated with white blood cell immunization is the possible transmission of infectious agents that the father's blood may be harboring. This can be avoided by testing his blood for any significant infections. Very uncommonly, there can be a local skin infection caused by bacteria on mother's own skin. This is easily treated.

Antiphospholipid Antibodies 


Phospholipid molecules are normal components of all cell membranes. Some also have glue like properties and allow cells to fuse (as you will see later). Antibodies to phospholipid molecules can, therefore, cause problems. Specifically, they can damage the inside of the blood vessel wall. This allows blood cells to stick to the site f the injury and cause blood clots (figure 3 & 4).
Some phospholipid molecules have adhesion properties i.e. glue like, and allow cells to fuse. The formation of the normal placenta involves the fusion of small cells called cytotrophoblasts into giant cells known as syncytiotro-phoblasts. The syncytiotrophoblasts play a key role in the regulation of nutrients going to the baby.

With each pregnancy loss, there is a 10% chance that the mother will develop an antibody to a phospholipid molecule (figure 2).

Most women with antiphospholipid antibodies are not sick. However, some have underlying autoimmune tendencies and should be appropriately evaluated. Women with underlying autoimmune diseases may have antiphospholipid antibodies even before they ever become pregnant. 

The treatment for antiphospholipid antibodies involves the use of low dose (baby) aspirin and a blood thinner called Heparin. Heparin is a very large molecule and is unable to cross the placenta. Aspirin is able to cross the placenta but the dose used is so small that the fetus is unaffected. The effectiveness of treatment is mush greater when the medication, if indicated, is started prior to conception and continued throughout the pregnancy. All medication, if indicated should be discussed with one's physician.

Antinuclear Antibodies 

The nucleus is the "brain" of the cell. It contains the information that regulates the function of the cell. Some people have antibodies to different nuclear components. What causes these antibodies to be made is currently under investigation but there appears to be a genetic susceptibility which may be reflected by the HLA tissue type (refer back to the section on blocking antibodies). 

The disease that we typically associate with antinuclear antibodies is Systemic Lupus Erythematosus (SLE). The miscarriage rate in SLE patients is much higher than that of the general population. Although most women who suffer recurrent miscarriages do not have clinical signs of SLE, many exhibit autoimmune phenomena which is similar to that seen in SLE patients. The placentas in these women are inflamed and weakened. 

The treatment for this problem is Prednisone, a corticosteroid, which suppresses the inflammatory process and stabilizes the cell. Prednisone does not pass through the placenta easily and is also broken down by enzymes in the placenta so that the fetus is exposed to only trace amounts. Additionally, the body produces the equivalent of 8 mg per day of this corticosteroid. When indicated, Prednisone should be started prior to conception. 

As the body is dynamic, antibody levels may change over time. This is illustrated in the figure below. Most people have no antinuclear antibodies all of the time (A,B). Many women who miscarry have borderline (C,D,E) or abnormal levels of antinuclear antibodies (F,G) (figure 5). 


Patients who develop new autoantibodies like antinuclear and antiphospholipid antibodies during pregnancy have a more guarded prognosis.


About William L. Matzner, M.D., PhD, FACP

Dr. William Matzner works in the area of healthcare economics consulting at Healthcare Analytics, LLC, in California. He graduated Phi Beta Kappa from Stanford University. He received his M.D. with Honors from Baylor College of Medicine. In 1988, he was the Solomon Scholar for Resident Research at Cedar Sinai Medical Center. Dr. Matzner subsequently was awarded a PhD in Neuro Economics from Claremont Graduate University. He is board certified in Internal Medicine and Palliative Medicine. He has researched and published extensively on the issue of reproduction and immunology in medical literature. He has been in private practice since 1989, specializing in Reproductive Immunology and Internal medicine.

Consulting Website: https://healthcareanalytics.biz
 
William Matzner, MD (Simi Valley, California), has been practicing medicine since 1989, Internal Medicine and Reproductive Immunology. M.D. with Honors from Baylor College of Medicine.

Featured Blog Article

New Review of Cost Effectiveness of Bundled Payments

  Dr. William Matzner, Simi Valley, California The cost of healthcare continues to be a topic of intense discussion from kitchen tables...